Disappointing the markets is becoming a habit
04/02/26 -"Even though the Q4 performance ensured that Novo delivered on the lowered 2025 expectations, the markets seem frustrated with the 2026 outlook, impacted by pricing and competitive pressures. After a ..."
Pages
76
Language
English
Published on
04/02/26
You may also be interested by these reports :
04/02/26
The Q4 performance, even though subdued, ensured that Novartis met the management’s 2025 guidance. Healthy Q4 growth across most key areas was ...
04/02/26
Even though the Q4 performance ensured that Novo delivered on the lowered 2025 expectations, the markets seem frustrated with the 2026 outlook, ...
03/02/26
Roche’s shares have recovered c.34% in the last three months and are now close to the highs witnessed in April 2022, as investors eventually recover ...
29/01/26
The 2025 performance delivered on the management’s guidance, backed by a strong showing from the cornerstone immunology medicine Dupixent, newly ...